Drug Shortage Report for AMIKACIN SULFATE INJECTION USP
Report ID | 253659 |
Drug Identification Number | 02242971 |
Brand name | AMIKACIN SULFATE INJECTION USP |
Common or Proper name | AMIKACIN SULFATE INJECTION USP |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | AMIKACIN |
Strength(s) | 250MG |
Dosage form(s) | LIQUID |
Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
Packaging size | 2ML |
ATC code | J01GB |
ATC description | AMINOGLYCOSIDE ANTIBACTERIALS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2025-03-31 |
Estimated end date | 2025-04-11 |
Actual end date | 2025-04-14 |
Shortage status | Resolved |
Updated date | 2025-04-15 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2025-04-15 | English | Compare |
v5 | 2025-04-14 | French | Compare |
v4 | 2025-04-14 | English | Compare |
v3 | 2025-04-01 | English | Compare |
v2 | 2025-03-31 | French | Compare |
v1 | 2025-03-31 | English | Compare |
Showing 1 to 6 of 6